zidesamtinib
Generic: Zidesamtinib
zidesamtinib: developed by 1 company · 2 clinical trials tracked.
zidesamtinib evidence translation
What we can confirm
2 tracked trials
What it means
Source-backed records connect zidesamtinib to NUVL; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could zidesamtinib → NUVL affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Locally Advanced Solid Tumor
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nuvalent, Inc. (NUVL) Locally Advanced Solid Tumor | Phase 1/Phase 2 |
Clinical Trials (2)
Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
Expanded Access30 sites · Australia, Belgium, Canada, France…Nuvalent Inc.
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
Primary endpoint: Maximum Tolerated Dose (MTD) (Phase 1)
Interventionalopen359 targetStarted 2022-01Completion 2028-1250 sites · Australia, Belgium, Canada, France…Nuvalent Inc.
Frequently asked questions
Who is developing zidesamtinib?
zidesamtinib is being developed by Nuvalent, Inc..
How many clinical trials involve zidesamtinib?
BioSniper tracks 2 clinical trials involving zidesamtinib.